Skip to main content
Consun Pharmaceutical Group Limited logo

Consun Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1681 HKEX Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2025-06-20 Governance Information
Country HK Hong Kong
Listing HKEX 1681

About Consun Pharmaceutical Group Limited

http://www.chinaconsun.com

Consun Pharmaceutical Group Limited is a modern pharmaceutical enterprise engaged in the integrated research, development, manufacturing, and marketing of pharmaceutical products. The company's core business is segmented into Modern Chinese Medicines (MCM) and Medical Contrast Medium products. The MCM portfolio targets major therapeutic areas, including chronic renal diseases (featuring products like Uremic Clearance Granules), liver and gallbladder conditions, and orthopedic trauma. In the medical imaging field, Consun supplies contrast agents such as Gadopentetate Dimeglumine Injection for magnetic resonance imaging (MRI) and Iopamidol Injection for angiography and neuro-radiology. The enterprise focuses on combining the modernization of Chinese medicine with advanced diagnostic solutions.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Governance Information Classification · 1% confidence The document provides a current list of the company’s board members and their committee roles, detailing the governance structure (board composition, committee chairmanships/memberships). It is not announcing a change in directors, nor is it an AGM presentation, financial report, or regulatory fallback. Instead, it describes internal governance arrangements and practices, fitting the Governance Information (CGR) category.
2025-06-20 English
CHANGES IN COMPOSITION OF THE NOMINATION COMMITTEE
Board/Management Information Classification · 1% confidence The document is an official announcement by a listed company regarding changes in the composition of its Nomination Committee, a committee of the Board of Directors. It does not present financial results, ESG metrics, or dividend details, nor is it a report publication notice. Instead, it concerns internal board governance and committee membership changes, fitting the Board/Management Information category (MANG).
2025-06-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued shares and treasury shares, including share repurchases for cancellation on specified dates. It is a direct report of the company buying back its own shares, matching the “Transaction in Own Shares” category.
2025-06-19 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a statutory “Next Day Disclosure Return” under the HKEX listing rules detailing both new shares issued (from option exercise) and shares repurchased (on-market buyback), including pricing, volumes, and confirmations under Main Board/GEM Rules. This is not an earnings release, annual report, or management discussion—it is a transaction report of the company’s own shares. Under the classification schema, this best matches the “Transaction in Own Shares” category (Code: POS).
2025-06-18 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Listing Rules detailing changes in issued shares and treasury shares, including a report on share repurchases (Part II) and confirmation of compliance, as well as an on-market sale of treasury shares section. This is a direct report of the company’s own share transactions (buyback and treasury sale) rather than a high-level capital raising announcement or generic regulatory notice. Therefore, it falls under the “Transaction in Own Shares” category (POS).
2025-06-17 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return filed under Hong Kong Stock Exchange rules detailing changes in issued shares (exercise of share options) and share repurchases (on-market buyback). It is a regulatory report of the company’s own share transactions (issuance and repurchase). This aligns with the category for Transaction in Own Shares (code POS).
2025-06-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.